TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07465757: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer

Sponsor: Puma Biotechnology, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,742,200

Rescue Site Savings

+$2,448,600

Unlock Full NCT07465757 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07465757 Rescue Dossier →